2022
Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study
Huang H, Datye A, Fan M, Knapp A, Nielsen T, Bottos A, Paulson J, Trask P, Efficace F. Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study. Cancer Medicine 2022, 11: 3312-3322. PMID: 35322932, PMCID: PMC9468432, DOI: 10.1002/cam4.4692.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaInternational Prognostic IndexProgression-free survivalLarge B-cell lymphomaB-cell lymphomaOverall survivalPrognostic valuePatient-reported outcomesPrognostic informationCox regression analysis of overall survivalClinical variablesAnalysis of overall survivalPhase III studyFifty-nine patientsCox regression analysisPatient risk stratificationPopulation of patientsEuropean Organization for Research and Treatment of Cancer Quality of LifeEuropean Organization for Research and TreatmentPlus chemotherapyIII studiesPrognostic indexTreatment of Cancer Quality of LifeGlobal health status/quality of lifeGlobal health status/qualityTRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma
Harris W, Bataillard E, Choi Y, El-Galaly T, Cuchelkar V, Henneges C, Kwan A, Schneider D, Paulson J, Nielsen T. TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma. JCO Clinical Cancer Informatics 2022, 6: e2100121. PMID: 35044836, DOI: 10.1200/cci.21.00121.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaR-CHOPFirst-line treatment of diffuse large B-cell lymphomaDiagnosed DLBCLTreatment of diffuse large B-cell lymphomaCourses of R-CHOPPresence of cardiovascular diseaseFirst-line treatmentProportion of patientsArea under the curveRoutine clinical settingCharlson Comorbidity IndexStandard of careHigh-risk categoryStandard chemoimmunotherapyChemotherapy toxicityCreatinine clearanceInferior outcomesBaseline characteristicsLogistic regression modelsComorbidity indexPatient frailtyEnd points
2019
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study
Bolen C, Klanova M, Trneny M, Sehn L, He J, Tong J, Paulson J, Kim E, Vitolo U, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard M. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica 2019, 105: 2298-2307. PMID: 33054054, PMCID: PMC7556630, DOI: 10.3324/haematol.2019.227892.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaPrognostic impact of somatic mutationsCell-of-origin subtypesBCL2 alterationsCell of originPrognostic impactImpact of somatic mutationsMolecular heterogeneity of diffuse large B-cell lymphomaGerminal center B-cell-like diffuse large B-cell lymphomaHeterogeneity of diffuse large B-cell lymphomaTargeted DNA next-generation sequencingAssociated with shorter progression-free survivalShorter progression-free survivalSomatic mutationsDNA next-generation sequencingParaffin-embedded tissue biopsiesProgression-free survivalMultivariate Cox regressionBCL2 translocationsUntreated patientsPotential treatment targetPrognostic differencesPrognostic effect